HUTCHMED Appoints Innovative Non-executive Director to Strengthen Board Committees

HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) is delighted to announce that Professor Solange Peters has been appointed as an Independent Non-executive Director, member of the Technical Committee and member of the Audit Committee of the Company, with effect from the conclusion of the annual general meeting of the Company to be held on May 12, 2023.

An acclaimed scientist and educator, Professor Peters is highly knowledgeable in the fields of oncology and immunology and is sure to make positive contributions to the Company.

Simon To, Chairman of HUTCHMED, warmly welcomed Professor Peters to the company. He expressed his belief that her expertise in biopharmaceutical research in oncology and immunology would be an invaluable asset for the company, and that she would be a major contributor in helping the company reach its targets.

Professor Peters is a renowned medical oncologist and thoracic malignancies specialist, chairing the Department of Oncology at the University Hospital of Lausanne in Lausanne, Switzerland. Having completed her prestigious clinical education in medical oncology and molecular biology in Switzerland and Italy, she has developed a deep expertise in thoracic tumors, lung cancer, and pleural tumors.

A major milestone in her career was being chosen as the youngest president of the European Society for Medical Oncology (ESMO) from 2020 to 2022, and she is actively involved in the educational programmes of ESMO, having created the Women for Oncology Committee. Additionally, Professor Peters was a member of the board of directors of the International Association for the Study of Lung Cancer (IASLC) from 2013 to 2017.

Professor Peters is a leader in thoracic malignancy at Lausanne University, where she is spearheading a translational programme in collaboration with the Swiss Federal Institute of Technology and the Ludwig Institute. Her research spans biomarker discovery and validation, multimodality strategies for locally advanced non-small cell lung cancer, and novel immunotherapy combinations and immuno-modulating treatments.

She is the local principal investigator for clinical trials at the Lausanne Cancer Centre, and a co-PI for various other trials. Her dedication to improving patient care and outcomes is exemplified by her pioneering research in the field.

Professor Peters is an esteemed member of the scientific, medical and corporate communities. She is the chair of the scientific committee and foundation council member of the ETOP IBCSG Partners Foundation, president of the Paris Saclay Cancer Cluster’s strategic advisory board, a board member of the Swiss National Cancer League, and president of the International Cancer Foundation.

As a corporate leader, she is an independent director of Galenica AG, which is listed on the SIX Swiss Exchange. Her impressive résumé speaks to her vast experience and dedication to her various fields.

Dr. Peters is an esteemed oncologist and academic, having authored more than 500 peer-reviewed manuscripts and book chapters, as well as acting as Associate Editor of the Annals of Oncology, Deputy Editor of Lung Cancer, and a board member of various other oncology journals. She also served as deputy editor of the Journal of Thoracic Oncology for an impressive ten-year period. Her impressive academic credentials include a doctorate in medicine and PhD from the University Hospital of Lausanne.

Professor Peters is a highly esteemed Independent Non-executive Director, member of the Technical Committee and member of the Audit Committee of HUTCHMED, having held no directorships or partnerships in the past five years. She has no relationship with any Directors, senior management or substantial or controlling shareholders of the Company, and no interest in the ordinary shares of HUTCHMED.

Her initial term of appointment will end at the next general meeting, subject to retirement in accordance with the Articles of Association and applicable legal and regulatory requirements. Her term will be automatically renewed for successive 12-month periods, unless she is not re-elected or her appointment is terminated.

As a reward for her valuable contributions, Professor Peters will receive director’s fees of US$76,000, US$8,000 and US$13,500 per annum respectively as an Independent Non-executive Director, member of the Technical Committee and member of the Audit Committee; such fees are subject to review and proration for any incomplete year of service.

In accordance with the AIM Rules for Companies and the HK Listing Rules, there is no further information that needs to be disclosed in relation to Professor Peters’ appointment as an independent director at HUTCHMED. We are pleased to welcome Professor Peters to the board and look forward to his valuable insight and expertise.


Hutchmed (Nasdaq/AIM: HCM; HKEX: 13) is a commercial-stage biopharmaceutical company that is on a mission to revolutionize cancer treatment and immunological diseases with innovative therapies.

Led by a team of 1,800 in oncology and immunology, Hutchmed has 5,000 personnel working around the world to bring its cutting-edge drug candidates from in-house discovery to patients everywhere. Already, three of its oncology drugs have made it to the market in China.

Leave a Comment